| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Alofanib (known aslso as RPT835) is a novel, potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2) with anticancer and antiangiogenic activity. In cancer cells expressing various FGFR2 isoforms, alofanib inhibited the phosphorylation of FRS2α with half maximal inhibitory concentrations (IC50) of 7 and 9 nmol/l. Alofanib inhibited FGF-mediated proliferation in a panel of four cell lines that represented several tumor types, including ovarian cancer, melanoma, and triple-negative breast cancer, with 50% growth inhibition (GI50) values ranging from 16 to 370 nmol/l. In comparison to brivanib and bevacizumab, alofanib dose-dependently inhibited the migration and proliferation of human and mouse endothelial cells (GI50 11-58 nmol/l). Alofanib treatment eliminated experimentally induced FGF-induced angiogenesis in vivo. Oral administration of alofanib produced strong antitumour activity and was well tolerated in a human tumour xenograft model driven by FGFR. Alofanib was noteworthy for its efficacy in models that expressed FGFR2. These findings demonstrate the effectiveness of alofanib as an FGFR2 inhibitor and offer compelling justification for its assessment in patients with FGFR2-driven malignancies.
| Targets |
FGFR2
|
|---|---|
| ln Vitro |
Alofanib primarily induces apoptosis through the cleavage of caspase 3, PARP, and Bcl-2 in SKOV3 cell line. The compound has little cytotoxic effect on ovarian cancer cells [1]. With IC50 values of 7 and 9 nmol/l, alofanib inhibits the phosphorylation of FRS2α in cancer cells expressing various FGFR2 isoforms. Alofanib inhibits FGF-mediated proliferation in a panel of four cell lines that represent several tumor types, including ovarian cancer, melanoma, and triple-negative breast cancer, with 50% growth inhibition (GI50) values ranging from 16 to 370 nmol/l. When compared to brivanib and bevacizumab, alofanib dose-dependently inhibits the migration and proliferation of human and mouse endothelial cells (GI50: 11-58 nmol/l)[2].
|
| ln Vivo |
The effectiveness of paclitaxel and carboplatin together was considerably enhanced by intravenous alofanib in a dose-dependent manner. In a mouse model of ovarian cancer, alofanib inhibits angiogenesis[1]. Oral alofanib administration is well tolerated and produces strong antitumour activity in a FGFR-driven human tumour xenograft model[2].
|
| Cell Assay |
After subjecting cells to alofanib (10, 100, and 1000 μM) for 72 hours, whole-cell lysates underwent immunoblotting analysis.
|
| Animal Protocol |
C57Bl/6 × DBA/2 F1 mice
15 mg/kg/d i.p. |
| References |
| Molecular Formula |
C19H15N3O6S
|
|---|---|
| Molecular Weight |
413.403903245926
|
| Exact Mass |
413.07
|
| Elemental Analysis |
C, 55.20; H, 3.66; N, 10.16; O, 23.22; S, 7.76
|
| CAS # |
1612888-66-0
|
| Related CAS # |
1612888-66-0
|
| Appearance |
Solid powder
|
| SMILES |
CC1=CC(=C(C=C1C2=CN=CC=C2)NS(=O)(=O)C3=CC=CC(=C3)C(=O)O)[N+](=O)[O-]
|
| InChi Key |
QUQGQIASFYWKAB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H15N3O6S/c1-12-8-18(22(25)26)17(10-16(12)14-5-3-7-20-11-14)21-29(27,28)15-6-2-4-13(9-15)19(23)24/h2-11,21H,1H3,(H,23,24)
|
| Chemical Name |
3-[(4-methyl-2-nitro-5-pyridin-3-ylphenyl)sulfamoyl]benzoic acid
|
| Synonyms |
RPT835; RPT-835; RPT 835
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 30.1 mg/mL (~72.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4190 mL | 12.0948 mL | 24.1896 mL | |
| 5 mM | 0.4838 mL | 2.4190 mL | 4.8379 mL | |
| 10 mM | 0.2419 mL | 1.2095 mL | 2.4190 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA